At PCI, ensuring life-changing medicines reach those who need it most is our highest priority. As a truly integrated global CDMO, we are manufacturing, packaging and supply chain experts, harnessing our experience and expertise to deliver you a seamless solution with the ultimate aim of improving the lives of patients.
As therapies become more complex with lower patient numbers per SKU and are often of a higher value, the complexity of stock management increases; however, by applying the principles of Late Stage Customization (LSC) and through investment in dedicated technology, we are able to offer a streamlined process that delivers cost and time efficiencies while minimizing risk.
Late Stage Customization (LSC) also referred to as digital printing, delivers an accelerated route to market quickly and efficiently, while reducing costs and complexity.
Digital printing enables customization of brite stock late in the production process or just prior to shipment, reducing supply chain risk through a more efficient stock management process. This service includes the in-line printing on blank roll stock, eliminating the need to pre-print multiple artworks and allowing for small unique batch production.
Printing digitally replaces the traditional plates and printing press
Capability to print on labels, pouches, blisters, and cartons
Ability to print both fixed and variable text including:
SKU specific artwork
Country specific language and/or protocols
Scarce and expensive drug product
Booklet labels: costly, complex, and patient unfriendly
Large percentage of booklets never opened
Risk of patients being non-compliant
Often countries are late in the clinical protocol and booklet labels need to be reordered or new labels applied
Shelf-life updates often result in relabeling activities
Increase in adaptive trials
Small batch sizes
MOQs drives waste and cost
Agility to react quickly to market needs/changes
Country specific labeling increases complexity
Availability and cost of bulk
Warehouse stock value
speed-to-study & market!
Quickly react to forecast changes, seasonality, and promotions
No component lead times with base stock in-house
Reduce lead time for packaged stock
Maximize use of product with short expiration dates or limited stability data
Reduce complexity in managing inventory
Reduce change overs and line clearance
Reduce waste of expensive drug products
More efficient use and distribution of expensive drug products
Decrease need of a second manufacturing run of drug products
No minimum order sizes from component vendors
Reduced loss from overstocking
Reduced stock holding in market with smaller MOQs
Positive effect on cash flow
Business continuity planning without the need for excessive safety stock